Vical Inc (VICL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- GDPH1730D
- Pages: 32
- October 2018
- Total Views:1181
- Region : North America
- GlobalData
- Equity Research Report

Details
Summary
Vical Inc (Vical) is a biopharmaceutical company, which focuses on research and development on DNA delivery technologies for the prevention and treatment of life-threatening diseases and vaccines for infectious diseases and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. Vaxfectin adjuvant is a proprietary cationic lipid-based formulation it is a protein-based vaccines. The company's DNA delivery technology takes up polynucleotide genetic material, such as DNA or RNA. The company has collaborations with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. Vical is headquartered in San Diego, California, the US.
Vical Inc (VICL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Content
Scope
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Vical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Vical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Vical Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Vical Enters into Partnership with Mycoses Study Group Education & Research Consortium 10
Vical Enters into Agreement with AnGes to Develop and Commercialize Equine Polyclonal Antibody Therapy 11
Licensing Agreements 12
Vical Enters into Licensing Agreement with Astellas Pharma for ASP2397 12
Vical Enters Into Licensing Agreement With Cyvax For Vaxfectin Adjuvant 14
Bristol-Myers Squibb Enters Into Licensing Agreement With Vical For Antibodies 15
Equity Offering 16
Vical Prices USD25 Million in Public Offering of Shares 16
Vical Raises up to USD7.8 Million in Private Placement of Shares 17
Vical Announces Public Offering Of Common Stock For Up To USD 50 Million 18
Vical, Biopharma Company, Completes Public Offering Of Common Stock For USD 52.2 Million 19
Vical Inc-Key Competitors 21
Vical Inc-Key Employees 22
Vical Inc-Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Financial Announcements 24
Aug 07, 2018: Vical reports second quarter 2018 financial and operational results 24
May 03, 2018: Vical Reports First Quarter 2018 Financial and Operational Results 25
Mar 15, 2018: Vical Reports Fourth Quarter 2017 Financial and Operational Results 26
Oct 23, 2017: Vical Reports Third Quarter 2017 Financial and Operational Results 27
Aug 08, 2017: Vical Reports Second Quarter 2017 Financial and Operational Results 28
May 15, 2017: Vical Reports First Quarter 2017 Financial Results 29
Mar 09, 2017: Vical Reports Fourth Quarter 2016 Financial Results 30
Government and Public Interest 31
Jan 29, 2018: Motif Bio, Spero Therapeutics and Vical Join Antimicrobials Working Group 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32
List Of Figure
List of Figures
Vical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Vical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Vical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Vical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Vical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Vical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
List Of Table
List of Tables
Vical Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Vical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vical Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Vical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Vical Enters into Partnership with Mycoses Study Group Education & Research Consortium 10
Vical Enters into Agreement with AnGes to Develop and Commercialize Equine Polyclonal Antibody Therapy 11
Vical Enters into Licensing Agreement with Astellas Pharma for ASP2397 12
Vical Enters Into Licensing Agreement With Cyvax For Vaxfectin Adjuvant 14
Bristol-Myers Squibb Enters Into Licensing Agreement With Vical For Antibodies 15
Vical Prices USD25 Million in Public Offering of Shares 16
Vical Raises up to USD7.8 Million in Private Placement of Shares 17
Vical Announces Public Offering Of Common Stock For Up To USD 50 Million 18
Vical, Biopharma Company, Completes Public Offering Of Common Stock For USD 52.2 Million 19
Vical Inc, Key Competitors 21
Vical Inc, Key Employees 22
Licence Rights
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Products
Vical Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Company Profile
Company Profile Title
Summary
Vical Inc (Vical) is a biopharmaceutical company, which focuses on research and development on DNA delivery technologies for the prevention and treatment of life-threatening diseases and vaccines for infectious diseases and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. Vaxfectin adjuvant is a proprietary cationic lipid-based formulation it is a protein-based vaccines. The company's DNA delivery technology takes up polynucleotide genetic material, such as DNA or RNA. The company has collaborations with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. Vical is headquartered in San Diego, California, the US.
Vical Inc (VICL)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Scope
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Vical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Vical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Vical Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Vical Enters into Partnership with Mycoses Study Group Education & Research Consortium 10
Vical Enters into Agreement with AnGes to Develop and Commercialize Equine Polyclonal Antibody Therapy 11
Licensing Agreements 12
Vical Enters into Licensing Agreement with Astellas Pharma for ASP2397 12
Vical Enters Into Licensing Agreement With Cyvax For Vaxfectin Adjuvant 14
Bristol-Myers Squibb Enters Into Licensing Agreement With Vical For Antibodies 15
Equity Offering 16
Vical Prices USD25 Million in Public Offering of Shares 16
Vical Raises up to USD7.8 Million in Private Placement of Shares 17
Vical Announces Public Offering Of Common Stock For Up To USD 50 Million 18
Vical, Biopharma Company, Completes Public Offering Of Common Stock For USD 52.2 Million 19
Vical Inc-Key Competitors 21
Vical Inc-Key Employees 22
Vical Inc-Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Financial Announcements 24
Aug 07, 2018: Vical reports second quarter 2018 financial and operational results 24
May 03, 2018: Vical Reports First Quarter 2018 Financial and Operational Results 25
Mar 15, 2018: Vical Reports Fourth Quarter 2017 Financial and Operational Results 26
Oct 23, 2017: Vical Reports Third Quarter 2017 Financial and Operational Results 27
Aug 08, 2017: Vical Reports Second Quarter 2017 Financial and Operational Results 28
May 15, 2017: Vical Reports First Quarter 2017 Financial Results 29
Mar 09, 2017: Vical Reports Fourth Quarter 2016 Financial Results 30
Government and Public Interest 31
Jan 29, 2018: Motif Bio, Spero Therapeutics and Vical Join Antimicrobials Working Group 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32
List Of Figure
List of Figures
Vical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Vical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Vical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Vical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Vical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Vical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
List Of Table
List of Tables
Vical Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Vical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vical Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Vical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Vical Enters into Partnership with Mycoses Study Group Education & Research Consortium 10
Vical Enters into Agreement with AnGes to Develop and Commercialize Equine Polyclonal Antibody Therapy 11
Vical Enters into Licensing Agreement with Astellas Pharma for ASP2397 12
Vical Enters Into Licensing Agreement With Cyvax For Vaxfectin Adjuvant 14
Bristol-Myers Squibb Enters Into Licensing Agreement With Vical For Antibodies 15
Vical Prices USD25 Million in Public Offering of Shares 16
Vical Raises up to USD7.8 Million in Private Placement of Shares 17
Vical Announces Public Offering Of Common Stock For Up To USD 50 Million 18
Vical, Biopharma Company, Completes Public Offering Of Common Stock For USD 52.2 Million 19
Vical Inc, Key Competitors 21
Vical Inc, Key Employees 22
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products
Vical Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.